All Type 2 diabetes articles
-
On demand webinarsReal-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer. View prescribing information Video: DPP-4 inhibitors webinar Click here to complete the feedback and receive your CPD certificate ...
-
Working party guideline/algorithm
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
-
NICE guideline
NICE type 2 diabetes guideline
This summary provides recommendations on blood glucose targets, patient education, and includes a useful algorithm on blood glucose management.
-
Prescribing summary card
Ozempic® ▼ (semaglutide) 1.34 mg/ml once‑weekly GLP-1 RA
Commissioned by Novo Nordisk Limited
-
Independent professional body guideline
Type 2 diabetes treatment pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
-
Independent professional body guideline
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
-
Guidance card
AWMSG card: Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼)
Information intended for healthcare professionals only. The production and printing of this Guidelines All Wales Medicines Strategy Group (AWMSG) card has been funded by Novo Nordisk Limited. Novo Nordisk Limited has reviewed this card for technical accuracy and regulatory compliance. This summary card only displays the ...
-
Video
Dr Kevin Fernando Q&A on type 2 diabetes
Dr Kevin Fernando answers questions on the impact of type 2 diabetes on patients’ daily lives, differences between NICE and SIGN guidance, and key take-home messages for primary care
-
Guidance card
Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼) SMC No. (2092)
Information intended for healthcare professionals only. The production and printing of this Guidelines SMC card has been funded by Novo Nordisk Limited. Novo Nordisk Limited has reviewed this card for technical accuracy and regulatory compliance. The SMC has reviewed this card for technical accuracy and permission request ...
-
Supplement
Type 2 diabetes: an overview of the SIGN guideline on pharmacological management of glycaemic control
Production of this Guidelines supplement has been funded by an educational grant from Napp Pharmaceuticals Limited. The grant included an honorarium for the author. Napp Pharmaceuticals Limited has reviewed the supplement for technical accuracy and to ensure compliance with regulations. Napp
-
Working party guideline/algorithm
Pancreatic exocrine insufficiency guideline
This management algorithm was developed by a multidisciplinary expert panel: Hambling C et al with the support of a grant from Mylan Ltd.
-
SIGN guideline
SIGN type 2 diabetes guideline
This summary provides key recommendations on lifestyle management, treatment options, diabetic CVD, and CKD. Includes a useful treatment algorithm
-
Test and reflect
NICE guideline on diabetes footcare
This CPD activity consists of 8 multiple-choice questions designed to test your knowledge on the management of diabetic foot problems
-
News
SIGN updates diabetes guidance
The Scottish Intercollegiate Guidelines Network has updated its guidance on the management of diabetes and published new guidance on pharmacological management of glycaemic control in people with type 2 diabetes.
-
News
NICE updates guidance on type 2 diabetes prevention
NICE has published an update to NICE Public Health Guideline 38 on Type 2 diabetes: prevention in people at high risk.
-
News
NHS England expands diabetes prevention programme
NHS England has expanded the Healthier You: NHS Diabetes Prevention Programme.
-
Independent professional body guideline
JBDS hyperglycaemia and steroid therapy guideline
A concise summary of JBDSIP's guideline on the management of hyperglycaemia and steroid (glucocorticoid) therapy outlined in two useful algorithms
-
Independent professional body guideline
JBDS-IP undergoing surgery and elective procedures guideline
This useful summary provides recommendations for primary care, and includes a GP letter with recommendations for referral of patients for surgery.
-
NICE guideline
NICE diabetes in children guideline
This summary includes recommendations on pharmacological therapy, recognition and management of diabetic ketoacidosis, and a care pathway.
-
NICE guideline
NICE diabetes in pregnancy guideline
An up-to-date summary of NICE guidance on diabetes management in pregnancy. Includes gestational diabetes, preconception, antenatal, and postnatal care.
